Group One Trading’s Apogee Therapeutics APGE Stock Holding History

Group One Trading’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.5K	Sell	237 -563	-70%	-$50.7K	﹤0.01%	5700
2026 Q1	$67.3K	Sell	800 -257	-24%	-$18.7K	﹤0.01%	5046
2025 Q4	$79.8K	Buy	+1,057	New	+$66.6K	﹤0.01%	5187
2025 Q3	–	Sell	-185	Closed	-$7.06K	–	8349
2025 Q2	$8.04K	Sell	185 -620	-77%	-$23.6K	﹤0.01%	6848
2025 Q1	$30.1K	Sell	805 -519	-39%	-$20.1K	﹤0.01%	5538
2024 Q4	$60K	Buy	1,324 +654	+98%	+$33.4K	﹤0.01%	4919
2024 Q3	$39.4K	Buy	670 +551	+463%	+$26.4K	﹤0.01%	4809
2024 Q2	$4.68K	Buy	+119	New	+$5.78K	﹤0.01%	5982

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Group One Trading's APGE Position: Q2 2026 in Review

Group One Trading reduced its Apogee Therapeutics (APGE) stake by 70% in Q2 2026, selling an estimated $50.7K and leaving 237 shares worth $31.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5700.

Group One Trading first reported a position in APGE in Q2 2024 and has held it in 8 quarters since. The position peaked at $79.8K in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Group One Trading held 237 shares of Apogee Therapeutics worth $31.5K as of Q2 2026.
Group One Trading sold 563 Apogee Therapeutics shares in Q2 2026, an estimated $50.7K.
Apogee Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5700 holding.
Group One Trading first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 8 quarters since.
Group One Trading's Apogee Therapeutics position peaked at $79.8K in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.